PHARMAQ part of Zoetis

What PHARMAQ part of Zoetis does

PHARMAQ, a wholly-owned subsidiary of Zoetis since 2015, is the global leader in fish health and vaccines for aquaculture, with 39 years of dedicated R&D and approximately 420 employees worldwide. Headquartered in Overhalla, Norway, the company operates through three integrated divisions: PHARMAQ (fish vaccines and therapeutics including injectable and bath/immersion vaccines, immune support, therapeutics, and biocides targeting salmon, tilapia, pangasius, sea bass, and cleaner fish), PHARMAQ Fishteq (vaccination machinery including NFT machines capable of injecting up to 4 vaccines per fish at 9,000 fish/hour and Micro-Matic syringes, plus on-site vaccination services that vaccinated over 66.5 million fish in 2023), and PHARMAQ Analytiq (diagnostic and analytical services including real-time RT-PCR, histopathology, microbiology, SmoltVision, NGS-based 16S community analysis, and data analytics delivered from laboratories in Norway, Scotland, Ireland, and Chile). The business generated 2 billion fish vaccine doses delivered in 2025 and serves commercial aquaculture producers globally.

The company operates a B2B enterprise sales model with owned subsidiaries in Norway, Chile, the UK, Vietnam, Turkey, Spain, Panama, and Hong Kong, distributing products across Europe, the Americas, and Asia. Revenue streams span vaccine and therapeutic product sales, vaccination equipment and on-site service contracts, and reference-laboratory diagnostic services. The customer experience is anchored by the iWISE digital health portal, which integrates sample registration, results delivery, and data analytics. PHARMAQ supplements organic capability with strategic acquisitions (Fish Vet Group in 2020, rebranded as PHARMAQ Analytiq; Nordland Sett Vaks in 2017) and partnerships with academic and government institutions including the Bill & Melinda Gates Foundation, NMBU, the Royal Veterinary College, the Norwegian Veterinary Institute, and Iceland's Sýni laboratory. Emerging capabilities include machine-learning histopathology scoring and an AI-driven "Sanitary Traffic Light" predictive health model for coho salmon, positioning the company at the intersection of animal health, aquaculture, and applied data analytics within Zoetis' broader portfolio.

Name

PHARMAQ part of Zoetis

Legal name

PHARMAQ AS

Website

https://pharmaq.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

101–250 employees

Short description

PHARMAQ, a Zoetis subsidiary, is the global leader in fish vaccines and aquaculture health, delivering 2 billion vaccine doses annually across vaccines, vaccination equipment (Fishteq), and diagnostic services (Analytiq) to commercial fish farmers worldwide.

Ownership category

akta.pro rank

Product category

Aquaculture Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Aquaculture (11251)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Aquaculture/Fish & Shrimp Vaccines (HLAMAKAE)

akta.pro secondary industries

Aquaculture & Fish Health Services (AFAEANAE), Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI)

Keywords

• Aquaculture vaccines
• Fish health products
• Vaccination equipment
• Fish diagnostic services
• Aquaculture therapeutics

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Fish Vaccines and Therapeutics: PHARMAQ develops and sells injectable and bath/immersion fish vaccines, immune support products, therapeutic products, and biocidal products. This is the core revenue stream, driven by recurring demand from fish farmers seeking to prevent disease and reduce antibiotic use.
2. Vaccination Equipment and Services (PHARMAQ Fishteq): Sale and servicing of NFT vaccination machines and Micro-Matic syringes, plus on-site vaccination services (machine vaccination and manual vaccination). In 2023, Fishteq vaccinated over 66.5 million fish across Norway, Sweden, and Scotland, achieving 99.35% optimal deposition quality.
3. Diagnostic and Analytical Services (PHARMAQ Analytiq): Reference laboratory and diagnostic services including PCR, histopathology, microbiology, SmoltVision, NGS, data analytics, and consultancy. Services are provided from laboratories in Norway, Scotland, Ireland, and Chile.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

PHARMAQ develops, manufactures and sells fish vaccines (injectable and bath/immersion), immune support products, therapeutics and biocidal products for the global aquaculture industry. The company also sells proprietary vaccination machinery (NFT machines and Micro-Matic syringes) through its Fishteq division, and operates reference diagnostic laboratories (PCR, histopathology, NGS, microbiology, SmoltVision) through its Analytiq division. Products and services target commercial fish farmers producing salmon, trout, tilapia, pangasius, sea bass and cleaner fish.

Product overview

PHARMAQ part of Zoetis operates as a unified platform-plus-modules portfolio organized across three divisions: PHARMAQ (vaccines and therapeutics), PHARMAQ Fishteq (vaccination equipment and services), and PHARMAQ Analytiq (diagnostics and research services). The core offering combines fish health products—injectable vaccines, bath vaccines, therapeutics, and biocides—with automated NFT vaccination machinery capable of delivering up to 4 vaccines per fish at 9,000 fish/hour. The diagnostic suite includes real-time RT-PCR, histopathology with digital pathology, microbiology, SmoltVision smoltification monitoring, NGS sequencing, and data analytics through the iWISE customer portal. These products are designed to work together: vaccines prevent disease, Fishteq equipment automates vaccination delivery, and Analytiq services provide laboratory diagnostics and insights that inform health management decisions across the aquaculture production cycle.

Differentiator

Problem solved

Functional benefit

Products and services

• PHARMAQ Fish Vaccines and Therapeutics Comprehensive portfolio of fish vaccines including injectable vaccines, bath/dip vaccines, immunosupport products, therapeutic products and biocide products used by commercial fish farmers to prevent and treat bacterial and viral diseases in salmonids, tilapia, pangasius, sea bass and cleaner fish.
• PHARMAQ Fishteq NFT Vaccination Machines Automatic fish vaccination machinery capable of injecting up to 4 vaccines in a single operation, available in three models supporting IP and IM simultaneous injection, with a maximum capacity of 9,000 fish per hour. Used by fish farmers for high-throughput automated vaccination of salmon and trout.
• PHARMAQ Fishteq Vaccination Services

Quantifiable outcome

• 2 billion fish vaccine doses delivered in 2025
• +5 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• SýnicoreStrategic or Co-development Partner · 22 September 2025Pharmaq Analytiq entered into a strategic partnership with Sýni, Iceland's leading privately owned laboratory, to establish a new and advanced diagnostic service tailored to the needs of the Icelandic aquaculture industry. The service launched in Q1 2026, combining Sýni's local expertise and laboratory operations with Pharmaq Analytiq's specialization in fish health and diagnostics.
• Norwegian University of Life Sciences (NMBU)coreStrategic or Co-development Partner · 10 December 2024Strategic partnership between PHARMAQ and NMBU to advance disease surveillance in tilapia farms across Sub-Saharan Africa. This collaboration is part of the A.L.P.H.A. Plus initiative, funded by Zoetis and the Bill & Melinda Gates Foundation. Professors Øystein Evensen and Stephen Mutoloki lead the scientific work from NMBU.
• Fish Vet Group (Benchmark Holdings)coreStrategic or Co-development Partner · 1 July 2020Zoetis acquired Fish Vet Group from Benchmark Holdings PLC in July 2020 as a strategic addition to its Pharmaq business. Fish Vet Group was rebranded to PHARMAQ Analytiq, more than doubling histopathology capacity and adding environmental testing services. Fish Vet Group was headquartered in Inverness, Scotland with labs in Norway, Ireland, and Chile.
• Royal Veterinary College (RVC), LondonminorStrategic or Co-development PartnerPHARMAQ participates in a research project at RVC in London which has, for the first time, comprehensively mapped the complete genetic material of fish viruses (PMCV and ILA) on a large scale. Several hundred genomes are whole-genome sequenced. The project is fully funded by the UK Biotechnology and Biological Science Research Council (BBSRC) and led by Dr. Sarah Hill at RVC.
• Veterinærinstituttet (Norwegian Veterinary Institute)minorStrategic or Co-development PartnerThe Norwegian Veterinary Institute developed MLVA analysis (Multiple Loci VNTR Analysis) for Moritella viscosa isolates, enabling mapping of genetic relationships between different isolates and identification of clonal complexes adapted to different fish species.
• Highlands and Islands Enterprise (HIE)minorStrategic or Co-development PartnerPHARMAQ Analytiq Scotland opened a new molecular diagnostic laboratory at Solasta House on Inverness Campus, developed by HIE. HIE is a development agency supporting the growth of the life sciences and technology sectors in the Scottish Highlands and Islands.
• ZoetiscoreOthersPHARMAQ was acquired by Zoetis in 2015 and operates as the aquaculture health business of Zoetis, the world leader in animal health. Zoetis provides global scale, resources, and corporate infrastructure.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• IDEXX Laboratories: Global leader in veterinary diagnostics with growing aquaculture and livestock testing services. Competes with PHARMAQ Analytiq in fish diagnostics and lab services, while serving a much broader veterinary and water-testing market.
• Virbac: Independent global animal health company offering vaccines, pharmaceuticals, and diagnostics across multiple species. Has aquaculture presence and competes in adjacent animal health categories, though aquaculture is not its primary focus.
• Elanco Animal Health: Large global animal health company with a multi-species portfolio including aquaculture products (aquaculture vaccines and parasiticides acquired from Bayer). Overlaps with PHARMAQ in fish vaccines but operates at much larger scale across livestock and companion animals.

Direct peers

• MSD Animal Health (Merck Animal Health): Global animal health division of Merck offering a portfolio of aquaculture vaccines (e.g., AquaVac) and therapeutics across salmon and warm-water species. Directly competes with PHARMAQ in fish vaccines globally, with comparable scale but a broader multi-species footprint.
• Ceva Santé Animale: Global animal health and vaccines player with an aquaculture portfolio (including Ceva Aqua) targeting salmon and warm-water species. Directly competes with PHARMAQ in fish vaccines, particularly in emerging markets and warm-water aquaculture.
• Benchmark Holdings: Animal health and aquaculture genetics company that previously owned Fish Vet Group (acquired by Zoetis/PHARMAQ in 2020) and competes in aquaculture diagnostics, health, and breeding. Directly comparable as a specialized aquaculture health platform, though with broader genetics exposure.
• HIPRA: Spanish animal health company with a growing aquaculture vaccines portfolio for salmon, sea bass, and other Mediterranean species. Competes directly with PHARMAQ in European aquaculture markets and has been expanding into Latin America.

Emerging players

• Indian Immunologicals: Indian animal vaccines manufacturer with an aquaculture vaccines portfolio targeting warm-water species (particularly Indian carp, shrimp). A growing emerging-market competitor to PHARMAQ in Asia's expanding aquaculture sector.
• AquaBounty Technologies: Aquaculture biotechnology company focused on genetically engineered salmon. Adjacent to PHARMAQ's customer base but operates in a different value chain layer (genetics/production) rather than vaccines and health services.

Others

• Skretting (Nutreco): Global aquaculture feed supplier and part of Nutreco. Does not compete directly with PHARMAQ but sits in the same aquaculture ecosystem, supplying feed to many of PHARMAQ's customers and increasingly integrating fish health offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/146287

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMAQ part of Zoetis